130 related articles for article (PubMed ID: 1968833)
1. Neurotransmitter and receptor alterations in the rat persistent dyskinesia model induced by iminodipropionitrile.
Ogawa N; Mizukawa K; Haba K; Sato H
Eur Neurol; 1990; 30 Suppl 1():31-40. PubMed ID: 1968833
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic ceruletide treatment on dopaminergic neurotransmitters, receptors and their mRNAs in the striatum of rats with dyskinesia induced by iminodipropionitrile.
Hirata H; Ogawa N; Asanuma M; Ota Z; Mori A
Brain Res; 1993 Feb; 604(1-2):197-204. PubMed ID: 8457848
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile.
Ogawa N; Haba K; Asanuma M; Mori A
Brain Res; 1991 Aug; 556(2):271-9. PubMed ID: 1933361
[TBL] [Abstract][Full Text] [Related]
4. Quantitative autoradiographic changes in 5-[3H]HT-labeled 5-HT1 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN).
Przedborski S; Wright M; Fahn S; Cadet JL
Neurosci Lett; 1990 Aug; 116(1-2):51-7. PubMed ID: 2259456
[TBL] [Abstract][Full Text] [Related]
5. Effects of repeated cyclosporin A administration on iminodipropionitrile-induced dyskinesia and TRE-/CRE-binding activities in rat brain.
Iida K; Iwata E; Asanuma M; Asanuma SN; Gómez-Vargas M; Miyazaki I; Nakanishi T; Ogawa N
Neurosci Res; 1998 Feb; 30(2):185-93. PubMed ID: 9579652
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
7. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
8. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
9. Proglumide, a cholecystokinin receptor antagonist, exacerbates beta, beta'-iminodipropionitrile-induced dyskinetic syndrome in rats.
Tariq M; Khan HA; Rehana Z; Al Moutaery K; Al Deeb S
Neurotoxicol Teratol; 1998; 20(5):571-9. PubMed ID: 9761597
[TBL] [Abstract][Full Text] [Related]
10. The iminodipropionitrile (IDPN) model of persistent spasmodic dyskinesias: regional serotonin metabolism in rat brain.
Cadet JL; Jackson-Lewis V; Fahn S
Brain Res; 1988 Jul; 456(2):371-4. PubMed ID: 2463039
[TBL] [Abstract][Full Text] [Related]
11. Tolerance to beta,beta'-iminodipropionitrile (IDPN)-induced neurobehavioural and vestibular toxicity in diabetic rats.
Tariq M; Khan HA; Moutaery KA; Deeb SA
J Appl Toxicol; 1999; 19(2):93-9. PubMed ID: 10215181
[TBL] [Abstract][Full Text] [Related]
12. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
13. The iminodipropionitrile (IDPN)-induced dyskinetic syndrome: behavioral and biochemical pharmacology.
Cadet JL
Neurosci Biobehav Rev; 1989; 13(1):39-45. PubMed ID: 2671832
[TBL] [Abstract][Full Text] [Related]
14. Differential changes in 125I-LSD-labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies.
Cadet JL; Kuyatt B; Fahn S; De Souza EB
Brain Res; 1987 Dec; 437(2):383-6. PubMed ID: 3435844
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
16. Increased cortical serotonin-2 (5-HT-2) receptors in the iminodipropionitrile (IDPN)-model of persistent dyskinesia in the rat.
Cadet JL; Rothman RB
Neuropeptides; 1987; 10(2):175-80. PubMed ID: 3683772
[TBL] [Abstract][Full Text] [Related]
17. Comparative dopamine-cholinergic mechanisms in the olfactory tubercle and the striatum: effects of metoclopramide.
Suarez-Roca H; Lovenberg T; Cubeddu LX
J Pharmacol Exp Ther; 1987 Dec; 243(3):840-51. PubMed ID: 3320346
[TBL] [Abstract][Full Text] [Related]
18. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of hydrocortisone on iminodipropionitrile-induced neurotoxicity in rats.
Tariq M; Khan HA; Siddiquei MM; Al Moutaery K; Al Deeb S
Basic Clin Pharmacol Toxicol; 2007 Mar; 100(3):176-81. PubMed ID: 17309521
[TBL] [Abstract][Full Text] [Related]
20. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
